These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 37995682)
1. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Nicosia L; Spencer GJ; Brooks N; Amaral FMR; Basma NJ; Chadwick JA; Revell B; Wingelhofer B; Maiques-Diaz A; Sinclair O; Camera F; Ciceri F; Wiseman DH; Pegg N; West W; Knurowski T; Frese K; Clegg K; Campbell VL; Cavet J; Copland M; Searle E; Somervaille TCP Cancer Cell; 2023 Dec; 41(12):2136-2153.e13. PubMed ID: 37995682 [TBL] [Abstract][Full Text] [Related]
2. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Conery AR; Centore RC; Neiss A; Keller PJ; Joshi S; Spillane KL; Sandy P; Hatton C; Pardo E; Zawadzke L; Bommi-Reddy A; Gascoigne KE; Bryant BM; Mertz JA; Sims RJ Elife; 2016 Jan; 5():. PubMed ID: 26731516 [TBL] [Abstract][Full Text] [Related]
3. Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. de Almeida Nagata DE; Chiang EY; Jhunjhunwala S; Caplazi P; Arumugam V; Modrusan Z; Chan E; Merchant M; Jin L; Arnott D; Romero FA; Magnuson S; Gascoigne KE; Grogan JL Cell Rep; 2019 Apr; 27(1):269-281.e4. PubMed ID: 30943407 [TBL] [Abstract][Full Text] [Related]
4. Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition. Shendy NAM; Bikowitz M; Sigua LH; Zhang Y; Mercier A; Khashana Y; Nance S; Liu Q; Delahunty IM; Robinson S; Goel V; Rees MG; Ronan MA; Wang T; Kocak M; Roth JA; Wang Y; Freeman BB; Orr BA; Abraham BJ; Roussel MF; Schonbrunn E; Qi J; Durbin AD Nat Commun; 2024 Apr; 15(1):3483. PubMed ID: 38664416 [TBL] [Abstract][Full Text] [Related]
5. Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma. Ryan KR; Giles F; Morgan GJ Eur J Haematol; 2021 Jan; 106(1):90-99. PubMed ID: 32997383 [TBL] [Abstract][Full Text] [Related]
6. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer. Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Spriano F; Gaudio E; Cascione L; Tarantelli C; Melle F; Motta G; Priebe V; Rinaldi A; Golino G; Mensah AA; Aresu L; Zucca E; Pileri S; Witcher M; Brown B; Wahlestedt C; Giles F; Stathis A; Bertoni F Blood Adv; 2020 Sep; 4(17):4124-4135. PubMed ID: 32882003 [TBL] [Abstract][Full Text] [Related]
10. CBP/p300 acetyltransferase activity in hematologic malignancies. Dutta R; Tiu B; Sakamoto KM Mol Genet Metab; 2016 Sep; 119(1-2):37-43. PubMed ID: 27380996 [TBL] [Abstract][Full Text] [Related]
11. Development of Dimethylisoxazole-Attached Imidazo[1,2- Muthengi A; Wimalasena VK; Yosief HO; Bikowitz MJ; Sigua LH; Wang T; Li D; Gaieb Z; Dhawan G; Liu S; Erickson J; Amaro RE; Schönbrunn E; Qi J; Zhang W J Med Chem; 2021 May; 64(9):5787-5801. PubMed ID: 33872011 [TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139 [TBL] [Abstract][Full Text] [Related]
13. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of (R)-5-methylpyrrolidin-2-ones as p300 bromodomain inhibitors with Anti-Tumor activities in multiple tumor lines. Liu R; Yang H; Chen Z; Zhou K; Shi Q; Li J; Huang Y; Huang X; Li Y Bioorg Chem; 2022 Jul; 124():105803. PubMed ID: 35439627 [TBL] [Abstract][Full Text] [Related]
15. Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain. Xu H; Luo G; Wu T; Hu J; Wang C; Wu X; Zhang Y; Xu Y; Xiang Q Biochem Biophys Res Commun; 2022 Oct; 623():17-22. PubMed ID: 35868068 [TBL] [Abstract][Full Text] [Related]
16. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines. Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771 [TBL] [Abstract][Full Text] [Related]
17. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP. Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer. Waddell A; Mahmud I; Ding H; Huo Z; Liao D Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199844 [TBL] [Abstract][Full Text] [Related]